ArticleJournal of applied clinical medical physics2026
Impact of variation in the α/β of cervical cancer on predicted clinical outcomes.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo improve the effectiveness and efficiency in radiation therapy, various treatment modalities and fractionation schemes have been introduced and combined for cancer treatment. Biological effective dose (BED) and equivalent dose in 2 Gy fraction (EQD PURPOSE: To investigate the impact of variation in the α/β of cervical cancer on the expected EQD
methodsA right-skewed log-normal distribution of experimentally derived α/β values was applied to a reference tumor control probability (TCP) curve generated from cervical cancer patients treated with radiation, and a population of patients following that distribution were simulated using Monte Carlo sampling. An alternate equation for equivalent dose in 2 Gy fractions (EQD
resultsVariation in α/β obtained from published experimental results produced potential losses in TCP of up to 24% in the range of clinical interest. RFLC curves predicted an optimal treatment dose of 95 Gy EQD
conclusionThe distribution of cervical cancer α/β values derived from experimental results produced significant changes in tumor control when applied to a reference TCP curve. TCP decreased with both the average and most probable α/β values. It is suggested that variance and heterogeneity in α/β be more explicitly incorporated to account for those patients that do deviate from the assumed constant value, especially in the case of evaluating different radiation schemes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.